摘要:
A process for the preparation of valgancyclovir which comprises: a) reacting a compound of formula 7, in an aprotic solvent, in the presence of a condensing agent, with a compound of formula 8, wherein R1, and R2 may be, each independently, hydrogen, an halogen atom or an hydroxyl group; the double bond may either be in the E or Z configuration or a mixture thereof to yield a compound of formula 9 b) mild hydrolysis of compound obtained in a) to give valgancyclovir.
摘要:
A process for the preparation of valgancyclovir which comprises: a) reacting a compound of formula 7, in an aprotic solvent, in the presence of a condensing agent, with a compound of formula 8, wherein R1, and R2 may be, each independently, hydrogen, an halogen atom or an hydroxyl group; the double bond may either be in the E or Z configuration or a mixture thereof to yield a compound of formula 9 b) mild hydrolysis of compound obtained in a) to give valgancyclovir.
摘要:
A process for the preparation of Rotigotine (I) and of pharmaceutically acceptable salts thereof, which comprises the reductive amination of an amine of formula 6 with the 2-thienylacetic acid-sodium boron hydride complex and which makes use of hydrobromide 5 as an intermediate (II) The process is advantageous from the industrial point of view in that it allows to obtain Rotigotine with high enantiomeric purity starting from optically active 5,6,7,8-tetrahydro-6-(S)-N-propylamino-1-methoxy-naphthalene (2), avoiding the use of dangerous reactives, the need for difficult chromatographic separation or the formation of by-products. Furthermore, two novel crystalline forms are disclosed.